Stonegate Investment Group LLC Has $224,000 Stock Position in Insulet Corporation $PODD

Stonegate Investment Group LLC lowered its position in Insulet Corporation (NASDAQ:PODD) by 96.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 726 shares of the medical instruments supplier’s stock after selling 19,037 shares during the quarter. Stonegate Investment Group LLC’s holdings in Insulet were worth $224,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. True Wealth Design LLC increased its holdings in Insulet by 288.0% in the third quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 72 shares during the last quarter. Golden State Wealth Management LLC grew its position in Insulet by 202.9% in the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after acquiring an additional 69 shares in the last quarter. Trust Co. of Toledo NA OH bought a new stake in Insulet in the second quarter worth approximately $35,000. Whittier Trust Co. of Nevada Inc. increased its stake in shares of Insulet by 48.9% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 43 shares during the last quarter. Finally, Quent Capital LLC bought a new position in shares of Insulet during the 3rd quarter valued at $49,000.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Canaccord Genuity Group upped their price objective on shares of Insulet from $432.00 to $450.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Royal Bank Of Canada upped their price target on Insulet from $370.00 to $380.00 and gave the stock an “outperform” rating in a research note on Friday, November 21st. Rothschild & Co Redburn raised their price objective on Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a research note on Friday, October 3rd. Stifel Nicolaus initiated coverage on Insulet in a report on Tuesday, October 21st. They issued a “buy” rating and a $370.00 target price for the company. Finally, Evercore ISI initiated coverage on Insulet in a report on Tuesday, December 16th. They set an “outperform” rating and a $370.00 price target on the stock. Twenty investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Insulet has a consensus rating of “Moderate Buy” and an average target price of $375.05.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $258.20 on Thursday. The company has a market cap of $18.16 billion, a price-to-earnings ratio of 74.84, a PEG ratio of 1.48 and a beta of 1.40. The business has a 50 day moving average price of $294.22 and a 200 day moving average price of $309.62. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.68. Insulet Corporation has a twelve month low of $230.05 and a twelve month high of $354.88.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. The company had revenue of $521.70 million during the quarter, compared to analyst estimates of $678.70 million. Insulet had a return on equity of 24.36% and a net margin of 9.76%.The company’s quarterly revenue was up 29.9% compared to the same quarter last year. During the same period in the previous year, the company earned $1.08 earnings per share. Research analysts predict that Insulet Corporation will post 3.92 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.